Figure 1 | British Journal of Cancer

Figure 1

From: Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results

Figure 1

Meta-analysis of the 10 evaluable studies assessing COX-2 in NSCLC. Hazard ratio and 95% CI of survival in studies evaluating COX-2 status in NSCLC. HR>1 implies a survival disadvantage for the group with COX-2 expression. The square size is proportional to the number of patients included in the study. The centre of the lozenge gives the combined HR of the meta-analysis and its extremities give the 95% CI. HR=1.39; CI 95% 0.97–1.99. Total number of patients: 1236.

Back to article page